LOUISVILLE, Ky., Dec. 2, 2020 /PRNewswire/ — Today the Gulf Medical University College of Medicine (GMU) and ScholarRx announced a collaboration to further the College’s educational mission. GMU has adopted the Rx Bricks online service from ScholarRx, a revolutionary digital learning platform that supports the curriculum and enhances pre-clinical instruction.
Prof. Hossam Hamdy, Chancellor, Gulf Medical University states, “Gulf Medical University’s partnership with ScholarRx ensures that the content of the medical curriculum is benchmarked with similar top U.S. medical colleges using the same program. The Rx Bricks of ScholarRx provide our students with up-to-date medical knowledge through educationally sound courses delivered by expert faculty. As a leading medical university in the Middle East, Gulf Medical University will contribute to the continuous development of ScholarRx by integrating its Virtual Patient Learning (VPL) technology in the Rx Bricks, conducting research, and evaluating the educational impact of ScholarRx. I am sure our students and faculty will appreciate the value of ScholarRx.”
GMU uses the innovative Rx Bricks digital learning platform from ScholarRx to better engage and align medical students with the curriculum. This has become especially important as more learning is taking place online. With this new set of resources, faculty teaching GMU students can:
- Assign specific Rx Bricks through their learning management system
- Use question banks accompanying the Rx Bricks for both formative and summative assessments, and
- Provide foundational support to their virtual patient learning sessions.
“Collaboration with ScholarRx has enriched and added value to our existing online learning resources, as the College of Medicine has been able to seamlessly integrate the Rx Bricks in the medical curriculum. Faculty and students alike have embraced it with ease due to the user-friendly nature of the resource,” said Prof. Manda Venkatramana, Vice-Chancellor Academics and Dean, College of Medicine at Gulf Medical University.
“GMU has developed into a leading institution for medical education in the Middle East under the visionary leadership of Chancellor Hamdy and Vice-Chancellor Manda,” said Dr. Tao Le, Founder and CEO of ScholarRx. “We are pleased to support their remarkable work in digital curricular innovation.”
About Gulf Medical University College of Medicine
The vision of the university is to be a leading international academic healthcare institution through the integration of quality health professions education, research, healthcare, and social accountability for sustainable community development. The College of Medicine, in existence since 1998, has managed to not only impart quality medical education, but has also created a network of healthcare services, a conducive research milieu, and developed unique related avenues for professional development, policy, and leadership to meet the healthcare needs of the nation and the region.
ScholarRx is a mission-driven education organization currently serving over 150,000 medical students and physician learners annually. ScholarRx has developed a revolutionary componentized, multi-competency curricular platform that empowers medical schools and their faculty to rapidly develop high-quality education experiences, even in resource-poor environments.
ST. LOUIS, Nov. 17, 2020 /PRNewswire/ — ClubReady, the leading provider of full-suite studio fitness and wellness club management software, today announced it will launch an integration with Factor4, the leading provider of gift card and loyalty solutions, this October. Amid the COVID-19 crisis, the global market for gift cards is estimated at $1 trillion this year and is projected to reach a revised size of $2.7 trillion by 2027. This integration will allow fitness studios, and their members, to benefit from this preferred and profitable method of gifting and payment.
“The ClubReady and Factor4 integration will provide our fitness studios customers access to a new revenue stream while adding value for their members,” said Fred Elias, Vice President of Business Development at ClubReady. “The gift program will also help studios acquire new members,” he explained. Studios can operate their gift card program out of a single management portal to view transaction data and trends. Factor4’s online gift card solution will enable studios to have custom branded pages integrated with ClubReady so members can purchase digital and plastic gift cards seamlessly from their websites. This is especially important considering the number of cards purchased online soared 57% in the first 6 months of this year compared to the first half of 2019, while purchases of digital gift cards jumped 61% comparatively, according to InComm.
“We are excited to partner with ClubReady and to provide fitness studios with a new revenue source that will help them recover from the COVID-19 closures that impacted the fitness industry,” said Dan Battista, Factor4 CEO. “Our solution complies with social distancing standards by enabling contactless delivery of gift cards via email and text, as well as the ability for members to pay by phone. Factor4 will help fitness studios use gift cards to attract new members and retain existing members.”
This integration provides fitness studios with versatility in developing their gift card programs. ClubReady and Factor4 estimate an implementation period of two to three weeks. With the integration complete, studios can launch their gift card program in time for the holiday season. Gift cards have been the most popular holiday gift to give and receive for 13 consecutive years. Learn more about this solution here.
Factor4, LLC was formed by four payment service experts to provide the premier gift card and loyalty solution. The founders’ strength comes from their combined industry expertise and extensive network. Factor4’s strength is from its best-in-class, proprietary platform, technology, integrations and team. The RewardOS API provides effortless, feature-rich integration to a wide range of point-of-sale devices. Factor4 boasts the most integrations of all gift and loyalty providers. Factor4 serves over 13,000 customers and growing. For more information, visit https://www.factor4gift.com/.
ClubReady is the leading provider of full-suite studio fitness and wellness club management software and services. Founded in 2009, ClubReady has been committed to building the studio fitness business of the future. The ClubReady Fitness Management Platform provides clients a full membership management and engagement
Greenwich LifeSciences, Inc. Announces Partnership with Baylor College of Medicine for its Planned Phase III Clinical Trial
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the formation of a partnership with Baylor College of Medicine in Houston, Texas to act as the lead clinical site for the Company’s upcoming Phase III clinical trial. Professor Mothaffar F. Rimawi has agreed to serve as the Global Principal Investigator of the Phase III clinical trial, and Professor C. Kent Osborne and Professor Rimawi are expected to serve as the first members of the Company’s Clinical Advisory Board for the development of GP2 immunotherapy across all indications and HER2 expressing cancers.
Snehal Patel, CEO of Greenwich LifeSciences, commented, “We are pleased to have entered into this collaboration with such prominent key opinion leaders who are truly committed to evaluating the potential of GP2 immunotherapy. Due to GP2’s safety profile, GP2 immunotherapy may provide clinicians with an option to deescalate treatment of patients by reducing the use of other, more toxic and expensive standard of care treatments. Both Professors Rimawi and Osborne have already introduced us to other breast cancer clinical sites and clinical leaders who have provided input into the design of the upcoming Phase III trial and who have expressed an interest in participating in the Phase III trial as high enrollment sites. In addition, we have also been jointly exploring the addition of both US and European breast cancer cooperative groups to more rapidly expand the clinical team.”
Professor Rimawi added, “We are excited to jointly evaluate the potential of GP2 immunotherapy. We believe that our patients will seek to participate in the upcoming trial as the GP2 Phase IIb clinical trial data suggests that GP2 could be both safe and effective and could be easily administered during standard of care follow-up visits. Our patients are seeking safe preventative treatments that allow them to transition away from the trauma of surgery, trastuzumab-based therapies, other HER2 targeted therapies, chemotherapy, and radiation as they seek to return to normal and healthy lives.”
Professor Osborne commented, “Bringing new alternatives to chemotherapy and improving quality of life for patients undergoing treatment for breast cancer are primary focuses of the Breast Cancer Program. GP2 immunotherapy may represent one such opportunity, and we look forward to collaborating with Greenwich LifeSciences and supporting the planned clinical trial with the resources of both the Dan L Duncan Comprehensive Cancer Center and the Baylor College of Medicine.”
Professor Mothaffar F. Rimawi is board certified in internal medicine, hematology and medical oncology, and serves as both Executive Medical Director and Co-Leader of the Breast Cancer Program at the Dan L Duncan Comprehensive Cancer Center.
Professor C. Kent Osborne is board certified in internal medicine, hematology and medical oncology, and serves as both the Tina and Dudley Sharp Chair in Oncology and the founding Director of the Dan L Duncan Comprehensive Cancer Center. Professor Osborne is also Professor of Medicine and Molecular and
Telix Pharmaceuticals and China Grand Pharma Announce Strategic Licence and Commercial Partnership for Greater China Market
MELBOURNE, Australia and HONG KONG, Nov. 02, 2020 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) announces it has entered into a strategic licence and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited (‘China Grand Pharma’) for Telix’s portfolio of Molecularly-Targeted Radiation (‘MTR’) products.
Telix has appointed China Grand Pharma as its exclusive partner for the Greater China market (‘Territory’)1 and grants China Grand Pharma exclusive development and commercialisation rights to Telix’s portfolio of prostate, renal and brain (glioblastoma) cancer imaging and therapeutic MTR products in the Territory.
Leveraging off China Grand Pharma’s capabilities and infrastructure in China, Telix will enter a significant oncology market, and by partnering with Telix, China Grand Pharma will build on its pipeline of innovative products for Greater China, as well as its strategy in Nuclear Medicine.
The material terms of the partnership include:
US$25M (~AU$35M) up-front non-refundable prepayment to Telix, to be credited against future regulatory and commercial milestone payments.
Up to US$225M (~AU$315M) in regulatory and commercial milestone payments to Telix, across Telix’s existing therapeutic products portfolio.
Program-related investment estimated at up to US$65M (~AU$90M) for clinical costs associated with the development of the therapeutic products in the Territory, to align with Telix’s global clinical development programs.
Royalties on therapeutic product sales in the Territory, in addition to milestone payments.
Exclusive commercial partnership (sales, marketing, distribution) for Telix’s core imaging product portfolio:
TLX250-CDx (89Zr-Girentuximab) for renal cancer, and;
TLX591-CDx (68Ga-PSMA), TLX599-CDx (99Tc-PSMA) for prostate cancer.
Strategic Equity Investment
Additionally, China Grand Pharma will make a simultaneous one-time strategic equity investment of US$25M (~AU$35M) in Telix. The investment is in the form of a private placement to China Grand Pharma of 20,947,181 fully paid ordinary Telix shares representing a post-issue holding by China Grand Pharma of 7.62%. Shares will be issued at a price of AU$1.69, based on the 10-day volume-weighted average price (‘VWAP’) for Telix shares up to and including 28th October 2020. Shares will be issued no later than November 06 2020, following receipt of the placement proceeds. Shares issued to China Grand Pharma are subject to a holding lock and will not be able to be traded for a period of 12 months from the date of issue. In addition, China Grand Pharma is subject to a standstill provision and is unable to trade in Telix shares for a period of 12 months.
Telix Pharmaceuticals CEO, Dr. Chris Behrenbruch stated, “Telix’s mission is to be a leading global oncology company and China is an important future market for our products. We are pleased to be working with China Grand Pharma to deliver our diagnostic imaging and therapeutic products to cancer patients in China. Considering the successful acquisition of Sirtex Medical Limited with joint venture private equity partner CDH Genetech Limited2 and subsequent approval of a New Drug Application filing for SIR-Spheres® by the National Medical Products Administration (‘NMPA’) of the
VeChain, Renji Hospital and DNV GL Held Strategic Partnership Signing Ceremony To Launch World’s First Blockchain Intelligent Tumor Treatment Center
SHANGHAI, Oct. 27, 2020 /PRNewswire/ — In partnership with VeChain and DNV GL, Renji Hospital, a top-ranked hospital in China affiliated with the Shanghai Jiaotong University School of Medicine, has announced the launch of the world’s first blockchain-enabled Intelligent Tumor Treatment Center on October 20, 2020. The Intelligent Tumor Treatment Center is a transparent, efficient, and traceable medical management solution powered by VeChain ToolChainTM.
As strategic partners of this new initiative, VeChain and DNV GL will jointly support the hospital in the quest to improve global public health through state-of-the-art blockchain technology and professional advisory.
VeChain ToolChainTM Powers The World’s First Intelligent Tumor Treatment Center
The Intelligent Tumor Treatment Center combines the advantages of VeChain blockchain technology with DNV GL’s professional services. It enables full patient ownership of personal medical records, allowing patients to take control of the authorization and medical records data management. Research institutions inside and outside the hospital can use authorized data to improve the efficiency of clinical research, and regulatory agencies can use authorized data to conduct business compliance checks on medical institutions and establish a credit evaluation system.
Zhang Jidong, Vice President of Renji Hospital, said, “The launch of the Intelligent Tumor Treatment Centre intends to enhance high-quality integrated development of Renji Hospital. Moving forward, Renji intends to boost our healthcare facilities with more blockchain-powered use cases and projects, which will be gradually disclosed together with our partners when the time is right.”
George Kang, Senior Vice President of DNV GL Group, said, “Through independent and objective medical evaluation methods, DNV GL intends to provide more services for Renji Hospital to improve its service quality and medical experience, moving to a new stage of higher standards, higher requirements and higher quality.”
Sunny Lu, co-founder and CEO of VeChain, said, “As digital transformation accelerates in the healthcare sector, VeChain will continue to demonstrate its advantages and flexibility as a superior blockchain platform that is suitable for all types of use cases and industries. We are very proud and excited to be contributing to the public health industry by providing the technology for Renji Hospital’s Intelligent Tumor Treatment Centre.”
VeChain Facilitating Digital Transformation To Improve Public Health
In line with the Chinese Government’s 14th Five-Year (2021-2025) Plan for Economic and Social Development, the National Health Commission formulated an official guideline and re-emphasized blockchain technology as an essential innovation and integration of the medical and health industry. VeChain is committed to solving the pain points of digital medical reform through blockchain technology and balancing personal privacy and public interests.
By using the self-developed one-stop data BaaS platform VeChain ToolChainTM , we have many proven cases in the medical sector, including a blockchain powered Clinical Trial Traceability Platform for Bayer China, and a blockchain-enabled medical data management platform named The E-NewHealthLife
DentaQuest Partnership and 120 Industry Leaders Create New Framework For More Sustainable Oral Health System
Three Domain Framework is the future of dentistry
Boston, Oct. 26, 2020 (GLOBE NEWSWIRE) — Even as the COVID-19 pandemic exacerbates the nation’s broken oral health care system, it has created an opportunity for the industry to move toward a new, more sustainable model centered around the patient, primary care and prevention. The DentaQuest Partnership for Oral Health Advancement released a report today — based on the work of the Community Oral Health Transformation Initiative learning community — that establishes a primary care-like structure for oral health care delivery, facilitates value-based payment models and enables patients to invest in their own oral health.
120 of the industry’s most prominent organizations and leaders contributed to the development of the Three Domain Framework, which lays out a clear path for providers and practices to expand access to care, improve health outcomes and reduce the cost burdens associated with poor quality of life due to oral disease.
The framework gives patients and dental and medical providers the freedom to collaborate on treatment plans that work best for a given situation within the context of overall health. And it emphasizes patient and provider safety while addressing critical gaps in both patients’ access to care and providers’ financial viability.
“Oral health is directly linked to overall health, but our current system doesn’t reflect that reality,” said Dr. Sean Boynes, vice president of health improvement for the DentaQuest Partnership for Oral Health Advancement. “And COVID-19 has shined a bright spotlight on this flaw. The Three Domain Framework outlines a new approach for oral health — one that focuses on prevention and healthy outcomes, facilitates value-based payment models, and will help address deep disparities in care and access. We are grateful to the many contributors who are working together to put our oral health system on a new and better path. This is the future of dentistry.”
The three domains can be adopted in any order, meaning the care team can determine where to begin. Providers can safely begin shifting their models of dentistry by starting in a domain that supports their unique needs and those of their patients.
Domain One: Advancements in Teledentistry
The pandemic has increased interest in and utilization of teledentistry, but widespread adoption requires defining new treatment codes and rethinking the flow of care for a variety of dental visits. Domain One focuses on the identification, development and adoption of telehealth strategies and builds an accessible evidence-based virtual delivery approach specific to oral health that can enhance disease prevention and whole-person health.
Domain Two: Prioritization of Minimally Invasive Care
The pandemic also sparked interest in Minimally Invasive Care (MIC), as providers sought treatment methods, like sealants and silver diamine fluoride, that limit aerosols and the spread of COVID-19. MIC can reverse or slow early disease stages using a program of anticipatory guidance and collaborative decision-making with patients. Domain Two prioritizes the use of MIC for oral health management and maintenance.
Domain Three: Integration and Personalization of Oral Care Delivery
Philips and Marienhospital Stuttgart sign 10-year strategic partnership to improve patient care and efficiency
October 21, 2020
Long-term agreement guarantees access to state-of-the-art solutions, controls costs, and ensures security of future investment
Fully-integrated approach deploying Philips’ digital healthcare solutions across multiple departments to enhance the experience of Marienhospital Stuttgart’s patient and staff
Amsterdam, the Netherlands and Stuttgart, Germany – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Marienhospital Stuttgart (Germany) today signed a 10-year strategic partnership agreement to expand world-class medicine at the hospital and provide integrated patient care. The project will include renewal and ongoing development of the hospital’s diagnostic imaging equipment and associated IT systems, digitization of its pathology department, and enhancement of the hospital’s emergency medicine capabilities.
Rather than treating each of these improvement areas as a separate exercise, Philips and Marienhospital Stuttgart will integrate them into connected patient care and optimized efficiency solutions. This will involve analysis of the hospital’s current treatment structures and pathways to enhance the overall quality of the hospital’s structures, processes and results, while also identifying potential cost savings. By jointly developing needs-based technology solutions, Marienhospital Stuttgart will be able to better plan its costs and ensure investment security in all areas.
“Due to the long-term nature of our partnership with Philips, our hospital will not only actively participate in future technological advances in healthcare, but also become a leader,” said Markus Mord, Managing Director of Marienhospital Stuttgart. “It will enable us to offer our patients diagnostic and therapeutic procedures that consistently meet the latest standards. We live medicine and always focus on the well-being of our patients.”
“As a solution provider, we specialize in partnering with our customers to provide integrated care concepts that enhance treatment pathways for their patients,” said Peter Vullinghs, Managing Director Philips DACH. “With new, highly innovative approaches, we will help to enhance the quality of medical care for the benefit of the patient across the board. We look forward to many years of mutual cooperation with Marienhospital Stuttgart.”
Reliable diagnosis through digital pathology
A core element of the collaboration is redesign of the hospital’s pathology department workflow, replacing conventional microscopes and glass slides with Philips’ high-performance digital pathology slide scanners and computer workstations. This will allow slide images to be managed, displayed, analyzed and discussed with clinical colleagues – for example, during tumor boards for the diagnosis and treatment of cancers. The ability to share slide images will also enable virtual consultations with experts from other hospitals. Competence networks like this combine the experience of doctors working in the clinic with the knowledge of their research colleagues, speeding up right-first-time diagnosis and the initiation of therapy.
Radiology for current and future needs
Reflecting the holistic nature of the partnership model, Philips will also help to analyze and redefine Marienhospital Stuttgart’s radiology procedures, processes and IT systems, as well as coordinating equipment renewal and expansion. Under the terms of the agreement, Philips will be responsible for the procurement, installation, maintenance (including updates and upgrades) and servicing of all large radiology equipment, with